SET and cancer: Using the recently described SET antagonist peptide, OP449, which has been reported to activate PP2A in multiple cancer cell types and inhibit relevant oncogenic pathways including c-Myc and Akt13, 17, 18, 19, 20, 21, we found that pharmacological inactivation of SET resulted in potent growth inhibition of enzalutamide resistant prostate cancers.